Sunpeaks Ventures Seeks Profits in $11.2 Billion Global Anticoagulant Market
SILVER SPRING, Md., March 7, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its' wholly owned subsidiary Healthcare Distribution Specialist, LLC ("HDS") are pleased to provide this update regarding the development and market potential of Clotamin®, an OTC multivitamin product owned and marketed by the Company.
Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners). According to BioMed Trends, in a report released by Global Industry Analysts, Inc., the global anticoagulants market is projected to surpass $11.2 billion by the year 2015, driven by an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors.
"The Warfarin market is absolutely enormous, – in fact, it's one of the Top 20 most prescribed drugs in the United States, with over 32 million prescriptions being written each year for approximately 6 to 7 million patients," stated Mackie A. Barch, CEO of Sunpeaks and longtime Warfarin patient. "By my calculations, if Sunpeaks is able to penetrate just 5% of the Warfarin market in just the U.S., sales for Clotamin could potentially surpass $25 million dollars annually. We look forward to ramping up our marketing and distribution efforts over the next few weeks and increasing awareness of Clotamin nationwide."
About Sunpeaks Ventures, Inc.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
For additional information, please visit www.sunpeaksventures.com.
Contact: Financial Insights 888-248-8491 or email@example.com
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Sunpeaks Ventures, Inc.Back to top